Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.

Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA.

Breast Cancer Res Treat. 2010 Feb;119(3):613-20. doi: 10.1007/s10549-009-0618-4.

2.

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA.

Breast Cancer Res Treat. 2011 Jun;127(3):681-8. doi: 10.1007/s10549-011-1450-1. Epub 2011 Mar 26.

3.

Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.

Korfage IJ, Fuhrel-Forbis A, Ubel PA, Zikmund-Fisher BJ, Greene SM, McClure JB, Smith DM, Alford SH, Fagerlin A.

Breast Cancer Res. 2013;15(5):R74.

4.

Testing whether decision aids introduce cognitive biases: results of a randomized trial.

Ubel PA, Smith DM, Zikmund-Fisher BJ, Derry HA, McClure J, Stark A, Wiese C, Greene S, Jankovic A, Fagerlin A.

Patient Educ Couns. 2010 Aug;80(2):158-63. doi: 10.1016/j.pec.2009.10.021. Epub 2009 Dec 9.

5.

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.

Cancer. 2005 May 15;103(10):1996-2005.

6.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

7.

Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs.

Zikmund-Fisher BJ, Ubel PA, Smith DM, Derry HA, McClure JB, Stark A, Pitsch RK, Fagerlin A.

Patient Educ Couns. 2008 Nov;73(2):209-14. doi: 10.1016/j.pec.2008.05.010.

8.

Breast cancer anxiety's associations with responses to a chemoprevention decision aid.

Dillard AJ, Scherer L, Ubel PA, Smith DM, Zikmund-Fisher BJ, McClure JB, Greene S, Stark A, Fagerlin A.

Soc Sci Med. 2013 Jan;77:13-9. doi: 10.1016/j.socscimed.2012.10.009. Epub 2012 Nov 2.

9.

Women's views on chemoprevention of breast cancer: qualitative study.

Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N.

Can Fam Physician. 2006 May;52:624-5.

10.

How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide.

McKay A, Martin W, Latosinsky S.

Breast Cancer Res Treat. 2005 Nov;94(2):153-9.

PMID:
16261414
11.

Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).

Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F, McCarthy N, Reaby L, Forbes JF.

Health Expect. 2008 Sep;11(3):252-62. doi: 10.1111/j.1369-7625.2008.00498.x.

12.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

PMID:
10547390
13.

Development and evaluation of a decision aid on mammography screening for women 75 years and older.

Schonberg MA, Hamel MB, Davis RB, Griggs MC, Wee CC, Fagerlin A, Marcantonio ER.

JAMA Intern Med. 2014 Mar;174(3):417-24. doi: 10.1001/jamainternmed.2013.13639.

14.

Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.

15.

Patient reluctance toward tamoxifen use for breast cancer primary prevention.

Port ER, Montgomery LL, Heerdt AS, Borgen PI.

Ann Surg Oncol. 2001 Aug;8(7):580-5.

PMID:
11508619
16.

Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory.

Ralph AF, Ager B, Bell ML, Collins IM, Andrews L, Tucker K, Phillips KA, Butow P.

Patient Educ Couns. 2014 Jul;96(1):106-12. doi: 10.1016/j.pec.2014.04.011. Epub 2014 Apr 28.

PMID:
24856850
17.

The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.

Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S.

Fam Cancer. 2005;4(2):97-103.

PMID:
15951959
18.

Affective forecasting and medication decision making in breast-cancer prevention.

Hoerger M, Scherer LD, Fagerlin A.

Health Psychol. 2016 Jun;35(6):594-603. doi: 10.1037/hea0000324. Epub 2016 Feb 11.

19.

"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.

Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R.

Ethn Dis. 2005 Summer;15(3):365-72.

PMID:
16108294
20.

Supplemental Content

Support Center